أفضل بودكاسات Synthesis Podcast Clinic (2024)

1
First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia 21:19

3d ago21:19

21:19

In this week's episode we’ll learn more about the ASCEND study, which investigated first-line asciminib in chronic phase chronic myeloid leukemia; a new risk score for myeloid neoplasm transformation in patients with clonal cytopenia of undetermined significance; and use of RHD genotyped D-positive blood transfusions in patients with sickle cell an…

1
Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML 19:03

10d ago19:03

19:03

In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab in previously untreated CLL. Then, we'll hear about dual epi-immunotherapy in classical Hodgkin lymphoma. Finally we'll explore redefining risk of treatment failure in CML. Featured Articles: Venetoclax-obinutuzumab for previously untreat…

1
Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis 20:32

17d ago20:32

20:32

In this week's episode we’ll learn more about the role of ERG loss-of-function variants in bone marrow failure and hematological malignancies, a proposed pathway linking factor 11 activation to increased vascular permeability during inflammation, and new clinical criteria for diagnosing anemia, defining transfusion-dependence, and evaluating anemia…

1
Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia ... 18:59

24d ago18:59

18:59

In this week's episode, we'll learn about the role of a platelet-specific glycoprotein receptor in abdominal aortic aneurysm formation, the influence of TP53 mutations on outcomes for patients with 5q-deleted myelodysplastic syndrome, and a rational combination treatment intended to produce more durable responses in patients with refractory B-cell …

1
Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS 21:48

1M ago21:48

21:48

In this week's episode we'll learn about refining risk stratification in T-cell acute lymphoblastic leukemia, or ALL. After that, we'll discuss a novel gene therapy approach in severe alpha-thalassemia. Investigators describe an innovative mouse model and an effective gene therapy approach, renewing prospects for the development of novel strategies…

1
A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT 18:30

1M ago18:30

18:30

In this week's episode we’ll discuss a novel tripartite fusion drives treatment resistance in acute promyelocytic leukemia. In some patients with atypical APL, these novel retinoic acid receptor gene fusions result in truncation of the ligand binding domain of the retinoic acid receptor protein, resulting in non-responsiveness to treatment with all…

1
Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis 23:17

1M ago23:17

23:17

In this week's episode we’ll discuss the safety and efficacy of pirtobrutinib with or without rituximab in relapsed/refractory CLL; learn more about erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine; and discuss how targeting PKC alpha alleviates iron overload in diabetes and hemochromatosis through …

1
Transplant outcomes in pediatric Fanconi anemia; hepatic Foxo1 regulates iron homeostasis; clinical networks improve APL outcomes in Latin America 18:42

2M ago18:42

18:42

In this week's episode we'll discuss outcomes following hematopoietic stem cell transplantation in pediatric patients with Fanconi anemia. Then, we'll learn about how new research shows that the transcription factor Foxo1, commonly associated with glucose metabolism, regulates hepcidin expression and systemic iron homeostasis. Finally, in Latin Ame…

1
CD8+ T-cell differentiation and treatment response in AML; ATM germline pathogenic variants affect cancer outcomes in ataxia-telangiectasia; efficacy of a selective menin-KMT2A inhibitor in KMT2A- and ... 22:42

2M ago22:42

22:42

In this week's episode we’ll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective m…

1
TCR-T cells for post-HCT leukemia recurrence; platelets are the predominant source of procoagulant membranes in hemostasis; BR + R maintenance for MCL 18:10

2M ago18:10

18:10

In this week's episode we'll discuss HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Next, we'll learn about how 4D intravital imaging in mice reveals the key role of platelets as a source of procoagulant membranes in hemostasis. Finally, we'll hear about modifications to a common i…

1
Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors 0:59

2M ago0:59

0:59

In this week's episode we’ll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors. Featu…

1
Review Series on Factor XI 44:40

2M ago44:40

44:40

Introduced by Associate Editor Dr. Thomas Ortel, this bonus episode discusses the Review Series on Factor XI, published in volume 143 issue 15 of Blood Journal. Dr. Ortel is joined by contributing authors Owen McCarty, PhD, Gili Kenet, MD, and David Gailani, MD. Review Series Articles: Introduction to a review series on factor XI Biology of factor …

1
Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL 16:56

3M ago16:56

16:56

In this week's episode we'll learn how cytomegalovirus infection early in life depletes preleukemic cells in a mouse model of B-cell acute lymphoblastic leukemia. After that we'll discuss new research, where GVHD targets organoid-forming bile duct stem cells in a TGF-beta-dependent manner. Conversely, a TGF-beta inhibitor protects these stem cells …

1
Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML 23:31

3M ago23:31

23:31

In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro an…

1
Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD 16:59

3M ago16:59

16:59

In this week's episode we’ll discuss how immune fitness impacts response to teclistamab in relapsed/refractory multiple myeloma; learn more about a new mechanism of resistance to asciminib conferred by the BCR::ABL1 M244V mutation, and discuss the impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell…

1
Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity ... 22:53

3M ago22:53

22:53

In this week's episode we’ll discuss the safety and efficacy of decitabine in older patients with AML; learn how heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice, and discuss the outcomes of treatment with HLA-mismatched HSCT with TCRab/CD19 lymphocyte depletion or post-HSCT cyclophosph…

1
Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism 21:50

4M ago21:50

21:50

In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. Featured Articles: EVIDENCE meta-analysis: evaluating minimal …

1
Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT 23:32

4M ago23:32

23:32

In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Featured Articles:…

1
Clinical impact of CRh in AML; thrombosis features in a real-life PNH cohort; and restriction of SOX11 expression to EBV-negative Burkitt lymphomas 19:58

4M ago19:58

19:58

In this week's episode we'll learn about the clinical benefit of complete remission with partial hematological recovery, or CRh, in patients with Acute Myeloid Leukemia (AML) treated with molecularly targeted drugs. Then we'll hear about a large cohort of patients with PNH were studied to detail PNH-related thrombotic events, unravel determinants o…

1
Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome 23:25

4M ago23:25

23:25

In this week's episode we’ll discuss the mutational and transcriptional landscape of pediatric BCP lymphoblastic leukemia; learn more about the role of platelet-derived TGF-β1 in immune thrombocytopenia; and discuss the findings from a phase 3 trial of mavorixafor in WHIM syndrome. Featured Articles: Mutational and transcriptional landscape of pedi…

1
GM-CSF coordinates shelter in the cytokine storm; Interleukin-1 as a therapeutic target in TTP; CAR T-cell outcomes across race and ethnicity in LBCL 19:57

5M ago19:57

19:57

In this week's episode we'll discuss new insights on the role of GM-CSF in establishing immune memory. The authors propose that the coordination of opposing immune memory programs, driven by GM-CSF, may be essential to efficient, yet controlled, innate immune responses. After that: Interleukin-1 inhibition in TTP. Researchers explore the potential …

1
Review Series on Oncogenic Signaling and Immune Evasion in Hematologic Malignancies 15:41

5M ago15:41

15:41

Introduced by Associate Editor Robert Zeiser, this Review Series focuses on the problem of immune escape by acute myeloid leukemia (AML). The series opens with a review of how AML escapes T-cell–driven elimination and then focuses on how p53 function impinges on AML recognition by immune cells. The series finishes with a summary of new approaches t…

1
Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease 23:39

5M ago23:39

23:39

In this week's episode we’ll discuss the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies, learn how peak ADAMTS13 activity can be used to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura, and discuss the findings from a phase …

1
A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy 19:16

5M ago19:16

19:16

In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell tran…

1
Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma ... 23:05

5M ago23:05

23:05

In this week's episode we’ll discuss the safety and efficacy of nilotinib with or without cytarabine in Philadelphia-positive acute lymphoblastic leukemia; learn more about thrombosis risk in double heterozygous carriers of Factor V Leiden and prothrombin G20210A and discuss the utility of circulating cell-free tumor DNA in prognostic prediction in…

1
Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML 18:59

5M ago18:59

18:59

In this week's episode we'll learn about fitusiran prophylaxis in patients with hemophilia A or B, with or without inhibitors. Next we'll hear about new findings that heterozygous germline variants in the NBN gene that are linked to increased risk of B-cell acute lymphoblastic leukemia in children. Finally, we'll explore new insights on the histone…

1
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia 22:26

6M ago22:26

22:26

In this week's episode we’ll discuss the effects of voxelotor on cerebral blood flow in pediatric sickle cell disease, learn more about venous and arterial thrombosis in patients with Vexas syndrome, and discuss differential sensitivity to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia. Featured Articles: The influence of voxe…

1
Stamping out high-risk myeloma with D-KRd and tandem transplant; plasmin-cleaved VWF in microthrombosis; SCD plasma sensitizes iPSC-derived sensory neurons 19:40

6M ago19:40

19:40

In this week's podcast we'll discuss another step forward in stamping out high-risk myeloma. Then we'll hear about the plasmin-cleaved von Willebrand factor, or VWF, in microthrombosis. Finally we'll hear about new insights into the origins of sickle cell pain. Featured Articles: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem…

1
Allogeneic transplant in first remission for post-induction molecular MRD; circulating HSPCs actively participate in human hematopoiesis; let-7 miRNAs repress HIC2 to regulate BCL11A transcription and ... 21:44

6M ago21:44

21:44

In this week's episode we’ll discuss the utility of MRD in identifying patients with NPM1 AML who benefit from allogeneic transplant in first remission, learn more about the contribution of circulating hematopoietic stem/progenitor cell subsets to human hematopoietic hemostasis, and discuss the role of Let-7 miRNAs in regulation of BCL11A transcrip…

1
ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins 19:10

6M ago19:10

19:10

In this week's epside we'll learn about ADAMTS recovery after caplacizumab therapy in patients with immune thrombotic thrombocytopenic purpura. Then, we'll hear about preclinical characterization of sonrotoclax, a potential second-generation BCL2 inhibitor. Finally we'll hear about new insights into the etiology of Castleman disease where researche…

1
Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction ... 23:49

7M ago23:49

23:49

In this week's episode, we’ll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and …

1
Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus? 19:00

7M ago19:00

19:00

In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients wi…

1
Jak2V617F clonal hematopoiesis promotes arterial thrombosis; Staphylococcus aureus infection in Sézary syndrome; clinical features of RAC2-related immunodeficiency 26:18

7M ago26:18

26:18

In this week's episode we’ll discuss the mechanism by which Jak2V617F clonal hematopoiesis promotes arterial thrombosis, discuss how Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome, and learn more about the clinical and functional features of RAC2-related immunodeficiency. Featured Articles: Jak2V617F clonal hemat…

1
Molecular mimicry in aplastic anemia; emicizumab prophylaxis in infants with hemophilia; hydroxyurea reduces infections in SCA 19:54

7M ago19:54

19:54

In this week's episode we'll discuss molecular mimicry in aplastic anemia, novel experiments show that antigens associated with viral infections can mimic epitopes presented on hematopoietic progenitor cells. Then, we'll learn about prophylaxis with subcutaneous emicizumab in infants with hemophilia. Finally we'll see how hydroxyurea is associated …

1
Review Series on the Influence of the Tumor Microenvironment on the Pathogenesis of B-Cell Lymphomas 32:05

8M ago32:05

32:05

In this bonus episode of Blood Podcast, Associate Editor, Dr. Freda Stevenson is joined by Drs. Karin Tarte, Andrea Radtke, and Leandro Cerchietti to discuss the Review Series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas. Find the full review series in Blood Journal volume 143 issue 12.…

1
Free light chain mass spectrometry in diagnosis and monitoring of AL amyloidosis; T cells of AML patients in remission have distinct RNA signatures; and protective effect of ADAMTS13 in sickle cell mice ... 22:34

8M ago22:34

22:34

In this week's episode we’ll discuss the findings from a study assessing the utility of free light chain mass spectrometry in AL amyloidosis, learn more about distinct single-cell RNA-sequencing signatures of bone marrow T cells of AML patients in remission after an allogeneic stem cell transplant, and discuss why von Willebrand factor clearance is…

1
Eculizumab in transplant-associated thrombotic microangiopathy; reclassifying malignant monocytosis; targeting tissue factor in antiphospholipid syndrome 20:50

8M ago20:50

20:50

In this week's episode we'll discuss eculizumab in stem cell transplant-associated thrombotic microangiopathy. Then, we'll learn about reclassifying malignant monocytosis, these newly classified cases have distinct mutational and transcriptional profiles. Finally, we'll hear about targeting the tissue factor coagulation initiation complex prevents …

1
Identification of rare relapse-initiating stem cells post-transplantation; interferon α impairs erythropoiesis in sickle cell disease; TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis ... 22:48

8M ago22:48

22:48

In this week's episode we’ll learn more about rare relapse-initiating stem cells in patients with MDS or AML in complete remission post-transplantation, discuss the role of interferon α in erythropoiesis in sickle cell disease, and learn more about how TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis.…

1
How PAR2 signaling drives thrombo-inflammation; pretransfusion hemoglobin levels linked to survival in beta-thalassemia; etoposide is better than its reputation in primary HLH 17:48

8M ago17:48

17:48

In this week's episode we'll discuss PAR2-biased signaling in thrombo-inflammation. Then, we'll learn about how hemoglobin levels are linked to survival in transfusion-dependent beta-thalassemia. Finally we'll hear about how etoposide is better than its reputation in primary HLH—hemophagocytic lymphohistiocytosis. Symptomatic patients treated with …

1
Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss 23:02

8M ago23:02

23:02

In this week's episode we’ll discuss the findings from a prospective trial of brentuximab vedotin with dacarbazine or nivolumab in older patients with classical Hodgkin lymphoma, learn more about CD20 antigen loss as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas, and discuss the role of trogocytosis in red blood…

1
CAR T cells plus ibrutinib in relapsed/refractory MCL; targeting SGF29 in AML; diffusion-limited oxygen release from stored blood 18:50

9M ago18:50

18:50

In this week's episode we'll discuss CAR T cells plus ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma. Next, we'll learn about a new SAGA for acute myeloid leukemia. Finally, we'll hear about new evidence that oxygen delivery to tissues can become diffusion-limited during perfusion with stored blood.…

1
Long-term outcomes of pulmonary embolism in children and adolescents; hereditary angioedema caused by a methionine-379 to lysine substitution in kininogens; predictors of loss of MRD negativity in multiple ... 25:07

9M ago25:07

25:07

In this week's episode we’ll report on the findings from a study evaluating the long-term outcomes of pulmonary embolism in children and adolescents, discuss a new mechanism for hereditary angioedema caused by a methionine-379 to lysine substitution in kininogens, and learn more about predictors of unsustained minimal residual disease negativity in…

1
Extended follow-up of axi-cel in indolent NHL; platelets help clear senescent RBCs; novel risk stratification strategy for CNS lymphoma 18:58

9M ago18:58

18:58

In this week's episode we'll discuss extended follow-up from the ZUMA-5 trial of axicabtagene ciloleucel, or axi-cel. Then we'll learn about the role of platelets in binding and clearing senescent red blood cells. Finally, we'll hear about a new risk stratification strategy for lymphomas of the central nervous system, or CNS.…

1
Lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma; reciprocal stabilization of coagulation factor XIII-A and -B subunits; inotuzumab ozogamicin for MRD in ALL 22:26

9M ago22:26

22:26

In this week's episode we’ll discuss the findings from a two-year follow-up study of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma, learn more about how reciprocal stabilization of coagulation factor XIII-A and -B subunits influences plasma FXIII concentration, and discuss the findings from a phase 2 study of inotuzumab o…

1
Maternal anticancer drug exposure and leukemia; PIEZO1-TMEM16F coupling in hereditary xerocytosis; NPM1 MRD during venetoclax therapy in NPM1-mutated AML 18:12

10M ago18:12

18:12

In this week’s episode, we’ll discuss the association between occupational exposure to anticancer agents in a parent and subsequent cancer in a child. Then we’ll learn about deciphering and disrupting the activation of PIEZO1 in hereditary xerocytosis. Finally, we’ll hear about the assessment of measurable residual disease, or MRD, in patients with…

1
TCRαβ/CD19-cell depleted haploHSCT for pediatric leukemia; malignancy-associated hemophagocytic lymphohistiocytosis in Sweden; the bone marrow as the primary site of thrombopoiesis 21:55

10M ago21:55

21:55

In this week's episode we’ll discuss the findings from a prospective trial of TCRαβ/CD19-cell depleted HLA-haploidentical transplantation to treat pediatric acute leukemia, learn more about the incidence, clinical characteristics, and survival of malignancy-associated hemophagocytic lymphohistiocytosis in Sweden, and discuss the bone marrow as the …

1
Fibrin polymerization and thrombosis; preventing CD19-negative relapse after CAR T-cell therapy in ALL; and impact of aberrant FUS condensates on HSC aging 18:00

10M ago18:00

18:00

In this week's episode we’ll explore the role of fibrinogen polymerization in thrombosis. Then, we’ll discuss preventing CD19-negative relapse after CAR T-cell therapy in acute lymphoblastic leukemia. Finally, we’ll learn how increased levels of the RNA-binding protein FUS has been identified as an effector of hematopoietic stem cell aging.…

1
CD24Fc for prevention of GVHD; origins of active EBV disease; the role of PF4 in platelet activation 21:45

10M ago21:45

21:45

In this week's episode we’ll discuss the findings from a phase 2 study of CD24Fc for prevention of graft-versus-host disease, learn more about the origins of chronic active Epstein-Barr virus disease, and discuss the role of PF4 in platelet activation.بقلم American Society of Hematology

1
Profiling a new VITT-like disorder; real-world outcomes of tafasitamab and lenalidomide in LBCL; and spatial mapping of human hematopoiesis 18:39

11M ago18:39

18:39

In this week's episode we'll uncover the clinical and pathological profile of a new disorder similar to VITT, or vaccine-induced thrombocytopenia and thrombosis. Then, we'll discuss real-world outcomes in patients with large B-cell lymphoma treated with tafasitamab and lenalidomide. Finally we'll learn about how advances in technology help unravel …

1
A natural history of familial platelet disorder with myeloid malignancy; HEXIM1 as an essential transcription regulator in erythropoiesis; residual disease predicts relapse in CML patients 21:53

11M ago21:53

21:53

In this week's episode we’ll discuss the findings from a natural history study of patients with familial platelet disorder with myeloid malignancy, learn more about the role of HEXIM1 as an essential transcription regulator in human erythropoiesis, and discuss the utility of residual disease as a predictor of relapse in CML patients stopping TKI th…

المدونة الصوتية تستحق الاستماع

Synthesis Podcast Clinic

المدونة الصوتية تستحق الاستماع

دليل مرجعي سريع